Medical oncologist Edith Mitchell, MD, director of Jefferson’s Center to Eliminate Cancer Disparities, appeared on OncLive discussing the growing number of treatment options for patients with colorectal cancer.
The U.S. Food and Drug Adminisration’s recent approval of the drug aflibercept for the treatment of metastatic colorectal cancer further expands the number of medications available for patients’ whose cancer has spread.
“Improvement in survival is what we’re talking about with colorectal cancer,” Dr. Mitchell tells OncLive, “improvement in how long the patients live as well as their quality of life.”
Read more here or watch the video below.
Increased number of medications oncologist have to treat patients with colorectal cancer is a key factor increasing the long-term survival of many people with this and other cancers.
“We have a number of patients who fit the criteria of chronic colorectal cancer,” she notes.